A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus
- Indications Liver cancer; Liver transplant rejection
- Focus Therapeutic Use
- 24 Oct 2019 Planned End Date changed from 1 Aug 2019 to 1 Jan 2021.
- 24 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Jan 2021.
- 24 Oct 2019 Status changed from recruiting to active, no longer recruiting.